South and Central America Late Stage Chronic Kidney Disease Drugs Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product Type (Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Others); Indication (Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalaemia); Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies); and Country

No. of Pages: 92    |    Report Code: TIPRE00018210    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
South and Central America Late Stage Chronic Kidney Disease Drugs Market

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. South and Central America Late Stage Chronic Kidney Disease Drugs Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. South and Central America Late Stage Chronic Kidney Disease Drugs Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 High Prevalence of Diseases Implying to Chronic Kidney Diseases
5.2 Market Opportunities
  • 5.2.1 Introduction of New Late Stage Chronic Kidney Disease Drugs
5.3 Future Trends
  • 5.3.1 Introducing New Preclinical Models to Improve Target Validation and Understand Disease Development
5.4 Impact of Drivers and Restraints

6. South and Central America Late Stage Chronic Kidney Disease Drugs Market Regional Analysis

6.1 South and Central America Late Stage Chronic Kidney Disease Drugs Market Overview
6.2 South and Central America Late Stage Chronic Kidney Disease Drugs Market Revenue 2017-2027 (US$ Million)
6.3 South and Central America Late Stage Chronic Kidney Disease Drugs Market Forecast Analysis

7. South and Central America Late Stage Chronic Kidney Disease Drugs Market Analysis – by Product Type

7.1 Calcimimetics
  • 7.1.1 Overview
  • 7.1.2 Calcimimetics: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Vitamin D
  • 7.2.1 Overview
  • 7.2.2 Vitamin D: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Sterols
  • 7.3.1 Overview
  • 7.3.2 Sterols: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Potassium Binders
  • 7.4.1 Overview
  • 7.4.2 Potassium Binders: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Calcium-Based Phosphate Binders
  • 7.5.1 Overview
  • 7.5.2 Calcium-Based Phosphate Binders: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2031 (US$ Million)

8. South and Central America Late Stage Chronic Kidney Disease Drugs Market Analysis – by Indication

8.1 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
  • 8.1.1 Overview
  • 8.1.2 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
8.2 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
  • 8.2.1 Overview
  • 8.2.2 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
8.3 Late Stage Chronic Kidney Disease Induced Hyperkalaemia
  • 8.3.1 Overview
  • 8.3.2 Late Stage Chronic Kidney Disease Induced Hyperkalaemia: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

9. South and Central America Late Stage Chronic Kidney Disease Drugs Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies
  • 9.1.1 Overview
  • 9.1.2 Late Stage Chronic Kidney Disease Induced Hyperkalaemia: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9.2 Online Pharmacies
  • 9.2.1 Overview
  • 9.2.2 Late Stage Chronic Kidney Disease Induced Hyperkalaemia: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9.3 Retail Pharmacies
  • 9.3.1 Overview
  • 9.3.2 Late Stage Chronic Kidney Disease Induced Hyperkalaemia: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

10. South and Central America Late Stage Chronic Kidney Disease Drugs Market – South and Central America Analysis

10.1 South and Central America
  • 10.1.1 South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Key Country, 2020 and 2027 (%)
  • 10.1.1.1 South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 Brazil: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.1.1 Brazil: South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
    • 10.1.1.1.2 Brazil: South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
    • 10.1.1.1.3 Brazil: South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
  • 10.1.1.2 Argentina: South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.2.1 Argentina: South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
    • 10.1.1.2.2 Argentina: South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
    • 10.1.1.2.3 Argentina: South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
  • 10.1.1.3 Rest of South and Central America : South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.3.1 Rest of South and Central America : South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
    • 10.1.1.3.2 Rest of South and Central America : South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
    • 10.1.1.3.3 Rest of South and Central America : South and Central America Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. South and Central America Late Stage Chronic Kidney Disease Drugs Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 AbbVie Inc
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Amgen
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 AstraZeneca
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Sanofi
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Kyowa Kirin Co., Ltd
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Bayer AG
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Vifor Pharma Management Ltd
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Akebia Therapeutics, Inc
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - South and Central America Late Stage Chronic Kidney Disease Drugs Market

  1.          AbbVie Inc
  2.          Amgen
  3.          AstraZeneca
  4.          Sanofi
  5.          Kyowa Kirin Co., Ltd
  6.          Bayer AG
  7.          Vifor Pharma Management Ltd
  8.          Akebia Therapeutics, Inc